61 phenotypes from 7 alleles in 7 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Fgf21tm1.1Djm/Fgf21tm1.1Djm involves: 129S6/SvEvTac * C57BL/6	abnormal gluconeogenesis	J:150831
	decreased circulating glucose level	J:150831
	decreased circulating ketone body level	J:150831
	decreased oxygen consumption	J:150831
	decreased physiological sensitivity to xenobiotic	J:150831
	hypoglycemia	J:150831
Fgf21tm1.2Djm/Fgf21tm1.2Djm involves: 129S6/SvEvTac * C57BL/6 * SJL	no abnormal phenotype detected	J:150831
Fgf21tm1Emf/Fgf21tm1Emf B6.Cg-Fgf21tm1Emf	abnormal adipose tissue morphology	J:157309
	abnormal blood homeostasis	J:157309
	abnormal body weight	J:157309
	abnormal brown fat cell morphology	J:157309
	abnormal food intake	J:157309
	abnormal glucose homeostasis	J:157309
	abnormal hypothalamus secretion	J:157309
	abnormal lipid homeostasis	J:157309
	abnormal lipid level	J:157309
	abnormal liver physiology	J:157309
	decreased body temperature	J:181337
	decreased fatty acids level	J:157309
	decreased locomotor activity	J:157309, J:181337
	decreased oxygen consumption	J:157309
	hepatic steatosis	J:157309
	impaired adaptive thermogenesis	J:181337
	impaired glucose tolerance	J:157309
	impaired lipolysis	J:157309
	increased body weight	J:157309
	increased brown adipose tissue amount	J:157309
	increased circulating cholesterol level	J:157309
	increased circulating glucose level	J:157309
	increased circulating insulin level	J:157309
	increased circulating leptin level	J:157309
	increased circulating triglyceride level	J:157309
	increased creatine kinase activity	J:181337
	increased gonadal fat pad weight	J:157309
	increased lean body mass	J:157309
	increased liver glycogen level	J:157309
	increased liver triglyceride level	J:157309
	increased liver weight	J:157309
	increased total body fat amount	J:157309
	increased white fat cell size	J:157309
Fgf21tm1Fdl/Fgf21tm1Fdl B6.Cg-Fgf21tm1Fdl	decreased circulating growth hormone level	J:184999
	decreased circulating insulin-like growth factor I level	J:184999
	increased body length	J:184999
	increased circulating growth hormone level	J:184999
	increased long bone epiphyseal plate size	J:184999
	increased width of hypertrophic chondrocyte zone	J:184999
	long tibia	J:184999
Fgf21tm1Lex/Fgf21tm1Lex involves: 129S5/SvEvBrd * C57BL/6N	abnormal brown adipose tissue physiology	J:240649
	abnormal brown adipose tissue thermogenesis	J:240649
	abnormal white adipose tissue physiology	J:240649
	decreased physiological sensitivity to xenobiotic	J:240649
Fgf21tm1Nit/Fgf21tm1Nit C57BL/6-Fgf21tm1Nit	abnormal circulating free fatty acids level	J:157334
	abnormal white fat cell size	J:157334
	normal behavior/neurological phenotype	J:157334
	decreased circulating free fatty acids level	J:157334
	decreased white adipose tissue amount	J:157334
	decreased white fat cell size	J:157334
	enhanced lipolysis	J:157334
	normal homeostasis/metabolism phenotype	J:157334
	impaired lipolysis	J:157334
	increased body weight	J:157334
	increased circulating free fatty acids level	J:157334
	increased circulating ketone body level	J:157334
	increased liver weight	J:157334
	increased white adipose tissue amount	J:157334
	increased white fat cell size	J:157334
Tg(Apoe-Fgf21)1Sakl/0 Not Specified	abnormal gluconeogenesis	J:150831
	increased liver glycogen level	J:150831
	increased oxygen consumption	J:150831